Insmed Inc. (INSM: Quote) said it appointed Will Lewis as president and chief executive officer, or CEO, effective immediately. Lewis has also been appointed to the company's Board of Directors. Lewis succeeds Tim Whitten, who has resigned as president and CEO and as a member of Insmed's Board of Directors.
Lewis has above 20 years of executive experience and a track record of success in the pharmaceutical and finance industries both in the U.S. and internationally. He is the former co-founder, president and chief financial officer of Aegerion Pharmaceuticals, Inc. (AEGR). During his tenure at Aegerion, he played a pivotal role in re-orienting the company's strategy to focus on orphan disease indications enabling Aegerion to go public in one of the best performing IPOs of 2010. Before joining Aegerion, he spent more than 10 years working in the U.S. and Europe in investment banking for JP Morgan, Robertson Stephens and Wells Fargo.
In addition, Insmed noted that Donald Hayden, Jr., who was appointed as executive chairman in May 2012, will return to his role as chairman, effective immediately.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org